Multiple Myeloma, also known as Myeloma or Plasma Cell Myeloma, is a type of cancer that affects plasma cells, which are responsible for producing antibodies to protect against infections. This disease can present in various ways, ranging from a slow-developing form with minimal protein abnormalities and few malignant cells to a rapidly progressing and life-threatening condition.
In this edition of our June 2024 Guidelines Rundown Series, we take a look at the current clinical practice guidelines for Multiple Myeloma, as well as provide insights into what the future holds for the remainder of 2024 and beyond. Additionally, we will touch on the latest FDA approvals for drugs and medications used for the treatment of Multiple Myeloma.
Newest Guidelines for Multiple Myeloma
- Optimal Use of T-Cell-Engaging Bispecific Antibodies in Multiple Myeloma
- International Myeloma Working Group (IMWG)
- May 2024
- Optimal Use of T-Cell-Engaging Bispecific Antibodies in Multiple Myeloma
- International Myeloma Working Group (IMWG)
- May 2024
- NCCN Guidelines for Multiple Myeloma
- National Comprehensive Cancer Network (NCCN)
- April 2024
Additional Current Guidelines for Multiple Myeloma
- Treatment of Multiple Myeloma
- American Society of Clinical Oncology/Cancer Care Ontario (ASCO/CCO)
- April 2019
- Multiple Myeloma Diagnosis, Treatment and Follow-Up
- European Hematology Association/European Society for Medical Oncology (EHA/ESMO)
- February 2021
- Immunotherapy for the Treatment of Multiple Myeloma
- Society for Immunotherapy of Cancer (SITC)
- July 2020 (focused update December 2022)
- Role of Bone-Modifying Agents in Multiple Myeloma
- ASCO
- January 2018
- Treatment of Metastatic Carcinoma and Myeloma of the Femur
- American Society for Radiation Oncology/ASCO/Musculoskeletal Tumor Society (ASTRO/ASCO/MTS)
- October 2020
- Infection Prevention in Multiple Myeloma
- IMWG
- February 2022
- Clinical Guideline for Multiple Myeloma
- Myeloma Australia
- June 2022
Looking Ahead
As we look to the rest of 2024, and even into 2025, there are a number of anticipated guideline updates and/or new guidelines in Multiple Myeloma. These include:
- ASCO Treatment of Multiple Myeloma Guideline Update
- NCCN guideline updates (ongoing)
- Additional IMWG guideline titles/updates
Noteworthy Recent FDA Approvals in Multiple Myeloma
- Medication: Talquetamab-tgvs (Talvey)
- Manufacturer: Janssen
- Approved: August 2023
- Indication: treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody
- Medication: Elranatamab-bcmm (Elrexfio)
- Manufacturer: Pfizer
- Approved: August 2023
- Indication: treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
- Medication: Motixafortide (Aphexda)
- Manufacturer: BioLineRx
- Approved: September 2023
- Indication: in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
- Medication: Ciltacabtagene autoleucel (Carvykti)
- Manufacturer: Janssen
- Approved: April 2024
- Indication: treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide
- Medication: Idecabtagene vicleucel (Abecma)
- Manufacturer: Bristol Myers Squibb
- Approved: April 2024
- Indication: treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and an anti-CD38 monoclonal antibody
There you have it – our Multiple Myeloma Guidelines Rundown for the month of June 2024. Did we miss anything? And what would you like to see us cover in our next edition of our Guidelines Rundown Series? Contact us today and let us know!
Copyright © 2024 Guideline Central, all rights reserved.